Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Maher (London, United Kingdom), G. Jenkins (Nottingham, United Kingdom), V. Cottin (Lyon, France), Y. Nishioka (Tokushima, Japan), I. Noth (Virginia, United States of America), M. Selman (Mexico City, Mexico), J. Song (Seoul, Republic of Korea), A. Prasse (Hannover, Germany), C. Ittrich (Biberach an der Riss, Germany), C. Diefenbach (Biberach an der Riss, Germany), K. Rohr (Ingelheim am Rhein, Germany), S. Stowasser (Ingelheim am Rhein, Germany), E. White (Michigan, United States of America). Blood biomarkers predicting disease progression in patients with IPF: data from the INMARK trial. 1922

Member's Comments

No comment yet.

Related content which might interest you: Effect of nintedanib on blood biomarkers in patients with IPF in the INMARK trial Source: International Congress 2019 – Biomarkers and beyond in idiopathic interstitial pneumonia Year: 2019 Blood biomarkers in COPD: results from the ECLIPSE (evaluation of COPD longitudinally to identify predictive surrogate endpoints) cohort Source: Annual Congress 2009 - Biomarkers, comorbidities and prognosis of COPD Year: 2009 Automatic quantitative fibrosis scores at baseline is a predictor of progression in patients with IPF Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): clinical problems Year: 2017 Stability of serum biomarkers and their associations with clinical outcomes in COPD patients and controls: a longitudinal study Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009 Disease progression at 12 months does not predict future outcomes in IPF patients: Analysis from the Australian IPF Registry Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Is blood eosinophil count a biomarker for chronic obstructive pulmonary disease in a real-world clinical setting? Predictive property and longitudinal stability in Japanese patients. Source: Virtual Congress 2021 – Patient-reported outcome measures (PROMs): easy tools in the management of chronic respiratory diseases Year: 2021 Modified GAP index by including serum KL-6 to assess risk of disease progression in patients with interstitial lung diseases (ILD): preliminary results from the VAMOS study. Source: Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes Year: 2021 Lung function indices versus symptoms for monitoring the course of the disease in patients with COPD Source: Annual Congress 2008 - Functionality and metabolism in rehabilitation candidates Year: 2008 Late Breaking Abstract - Prognostic value of serum biomarkers in patients with idiopathic pulmonary fibrosis and correlation with disease progression. Source: Virtual Congress 2021 – Exercise tolerance, supportive care and more in non-pulmonary fibrosis interstitial lung diseases Year: 2021 Mortality risk prediction in COPD by a prognostic biomarker panel – Results of a derivation and validation cohort with a long term follow-up Source: International Congress 2014 – Markers Year: 2014 Blood monocyte counts as a potential prognostic marker for idiopathic pulmonary fibrosis: analysis from the Australian IPF registry Source: Eur Respir J, 55 (4) 1901855; 10.1183/13993003.01855-2019 Year: 2020 Monitoring disease progression in COPD patients: one step beyond! Source: Eur Respir J 2014; 43: 665-667 Year: 2014 Novel patterns of serum biomarkers profiling using minimal important clinical outcomes (MICO) in the longidutinal study BODE cohort of COPD patients Source: Annual Congress 2010 - COPD: symptoms and staging Year: 2010 Serum exosomes from IPF patients display a fibrotic miRNA profile that correlates to clinical measures of disease severity Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Does anti-acid treatment influence disease progression in SSc-ILD ? data from the German SSc-network Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019 Relationship of baseline or annual change of clinical parameters on mortality in patients with COPD Source: Annual Congress 2013 –Risk factors for COPD and lung function decline Year: 2013 Plasma metabolomic signature in COPD patients: Associations to proteomic profile and clinical outcomes Source: Annual Congress 2013 –COPD mechanisms Year: 2013 Can clinical data predict rapid decline of lung function in idiopathic pulmonary fibrosis (IPF) patients? Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 Incidence of multiple progression events in patients with idiopathic pulmonary fibrosis (IPF) in the pooled CAPACITY and ASCEND trials Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 Blood biomarker algorithms to guide COPD assessment and risk stratification Source: International Congress 2017 – Towards personalised medicine in COPD: biological and clinical phenotypes Year: 2017